The resumption of trading for NGM Biopharmaceuticals shares suggests that any issues leading to the halt have been addressed, allowing the stock to return to the market. This event is directly relevant to NGM and its investors, though the impact on the stock's price in the short term is uncertain without additional context regarding the reason for the halt.